BPC-157 + TB-500 10mg / 20mg

Buy high-purity BPC-157 + TB-500 blend in Australia (10mg / 20mg). Third-party lab tested at >99% purity. Australian-domestic shipping, AUD pricing, supplied for laboratory research use only.

About the BPC-157 + TB-500 blend

The BPC-157 + TB-500 blend pairs two of the most extensively studied research peptides in tissue-repair and regenerative biology in a single lyophilised vial. BPC-157, a stable 15-amino-acid pentadecapeptide derived from a fragment of human gastric juice protein BPC, has been characterised in published research for its effects on angiogenesis, growth-factor signalling and connective-tissue repair across a wide range of injury models. TB-500 is a synthetic 17-amino-acid fragment of thymosin β-4 (Tβ4) corresponding to the actin-binding region, studied for its effects on cell migration, actin remodelling and microvascular development. Combined in equal-mass ratios, the blend is a frequently chosen tool in animal-model research where complementary repair pathways are examined in parallel.

Optic Labs supplies the BPC-157 + TB-500 blend in Australia as a co-lyophilised powder in two formats — 10mg total (5mg BPC-157 + 5mg TB-500) and 20mg total (10mg BPC-157 + 10mg TB-500) — third-party HPLC verified at >99% purity for both peptides. The blend is supplied strictly for laboratory research use only and is not intended for human consumption, clinical, cosmetic, diagnostic or veterinary application.

Product specifications

• Compound: BPC-157 + TB-500 co-lyophilised blend
• BPC-157 CAS: 137525-51-0  |  TB-500 CAS: 77591-33-4
• BPC-157 sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (pentadecapeptide, ~1419.5 g/mol)
• TB-500 sequence: Ac-LKKTETQ (active fragment of thymosin β-4 17-mer, ~889.0 g/mol; full TB-500 17-mer ~1894.2 g/mol depending on supplier definition)
• Form: Lyophilised powder (co-formulated)
• Purity: >99% by HPLC for each peptide
• Available sizes: 10mg total (5mg + 5mg) and 20mg total (10mg + 10mg)
• Storage: 2–8°C, protect from light. Reconstituted: 2–8°C, used within 30 days.
• Origin: Manufactured to research-grade specifications, third-party HPLC verified
• Shipping: Australia-wide domestic dispatch from Sydney, NSW

Research background

BPC-157 and TB-500 are often co-studied because their published mechanisms operate on complementary axes of tissue repair — BPC-157 on angiogenic, nitric-oxide and growth-factor pathways; TB-500 on actin sequestration, cell migration and microvasculature. Researchers combine them to probe whether parallel pathway engagement produces additive or distinct effects in connective-tissue, gastrointestinal and cardiovascular injury models.

• BPC-157: tendon-to-bone and ligament-healing models examining fibroblast proliferation and outgrowth in rats and rabbits.
• BPC-157: gastrointestinal-protection research in models of ulcerative damage, inflammatory bowel disease and short-bowel syndrome.
• BPC-157: angiogenic and VEGF/eNOS pathway signalling in wound and vascular research.
• TB-500: G-actin sequestration and actin-cytoskeleton remodelling in cell-migration assays.
• TB-500: cardiac-repair models examining epicardial cell activation and capillary density post-infarction.
• TB-500: corneal, dermal and hair-follicle research examining keratinocyte and endothelial migration.
• Combined in-vivo studies in rodent musculoskeletal-injury models examining whether co-administration alters repair time-course versus single-peptide arms.

For deeper background on each peptide, see our BPC-157 + TB-500 stack research guide, our BPC-157 complete research guide and our TB-500 thymosin β-4 research guide. Researchers working with reconstitution should also reference our peptide reconstitution guide.

Reconstitution and handling

The blend is supplied co-lyophilised, meaning both peptides are dissolved together when the vial is reconstituted. Use sterile bacteriostatic water. For the 10mg blend (5mg + 5mg), adding 2mL of bacteriostatic water yields 2.5mg/mL of each peptide (5mg/mL total peptide); 1mL gives 5mg/mL of each (10mg/mL total). For the 20mg blend (10mg + 10mg), 2mL of bacteriostatic water gives 5mg/mL of each peptide (10mg/mL total). Add diluent slowly down the side of the vial — do not inject directly onto the lyophilised cake — and allow the powder to dissolve without vigorous shaking. Reconstituted blend should be stored at 2–8°C, protected from light, and used within 30 days. For worked dilution examples for any vial size, see our peptide reconstitution calculator guide and our peptide storage guide.

Commonly stacked research peptides

The BPC-157 + TB-500 blend sits at the centre of the broader tissue-repair and regenerative-research family. Researchers studying related repair pathways often hold the constituent peptides on hand individually, alongside connective-tissue and anti-inflammatory tools:

• BPC-157 — single-compound vial for protocols that require BPC-157 alone or at a non-1:1 ratio to TB-500.
• TB-500 — single-compound vial for protocols that require TB-500 alone.
• GHK-Cu — copper-binding tripeptide studied in collagen synthesis, dermal repair and angiogenesis research.
• KPV — α-MSH-derived tripeptide examined in anti-inflammatory and gut-barrier research, often run alongside repair stacks.
• GLOW70 stack — pre-blended BPC-157 + GHK-Cu + TB-500 for researchers needing a three-compound combination.

For broader stack-design context, see our peptide research stacks overview.

Frequently asked questions

Is the BPC-157 + TB-500 blend legal in Australia?

Neither BPC-157 nor TB-500 is an approved therapeutic good in Australia, and neither peptide is registered with the Therapeutic Goods Administration (TGA). Optic Labs supplies the blend strictly for laboratory research, development and analytical use — not for human consumption, clinical or cosmetic application. For a detailed overview of how research peptides sit within the Australian regulatory framework, see our guide to peptide legality and TGA compliance in Australia.

What is the BPC-157 + TB-500 blend?

It is a co-lyophilised vial containing equal masses of BPC-157 (a pentadecapeptide derived from gastric juice protein BPC) and TB-500 (a fragment of thymosin β-4). The two peptides are widely studied together in tissue-repair, gastrointestinal and cardiovascular injury models. For background on each, see our BPC-157 + TB-500 stack research guide.

Why use a blend instead of running BPC-157 and TB-500 from separate vials?

A co-lyophilised blend reduces handling steps and the number of reconstitution events, which is convenient when a research protocol consistently uses the two peptides at a 1:1 mass ratio. For protocols that require unequal ratios, dose-escalation across one peptide while holding the other constant, or single-peptide arms, separate BPC-157 and TB-500 vials are the appropriate choice.

How much bacteriostatic water do I mix with a BPC-157 + TB-500 vial?

For the 10mg blend (5mg BPC-157 + 5mg TB-500), 2mL of bacteriostatic water gives 2.5mg/mL of each peptide. For the 20mg blend (10mg + 10mg), 2mL gives 5mg/mL of each. See our reconstitution calculator guide for additional worked examples.

How should the reconstituted blend be stored?

Reconstituted blend should be stored at 2–8°C, protected from light, and used within 30 days. Lyophilised vials are stable at 2–8°C until reconstitution. For full handling guidance, see our peptide storage research guide.

Where does Optic Labs ship to?

Optic Labs ships Australia-wide from Sydney, NSW. Standard dispatch is next business day on orders received before the daily cut-off. International shipping is not currently offered.

Legal disclaimer

All products on this site are supplied for laboratory research, development or analytical use only. They are not for human consumption, clinical use, or any diagnostic, cosmetic or veterinary application. These products and statements have not been evaluated by the Therapeutic Goods Administration (TGA) or the APVMA and are not intended to diagnose, treat, cure or prevent any disease. Optic Labs is not a compounding pharmacy or manufacturing facility as defined under the Therapeutic Goods Act 1989, and is not a registered provider of scheduled medicines or therapeutic goods.